Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

4 Oct 2017

Abstract excerpt

Abstract Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC). Recent reports suggest that drug resistance is driven by tumor adaptation via epigenetic mechanisms that activate alternative survival pathways. The histone methyl transferase EZH2 is frequently altered in many cancers, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28978636
DOI: 10.1158/0008-5472.can-17-0899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome ReprogrammingPMID 28978636Read ↗

Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.Semantic proximity Read ↗

Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic ModificationsSemantic proximity Read ↗

HDAC8 Enhances the Function of HIF‐2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCCSemantic proximity Read ↗

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancerSemantic proximity Read ↗

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.Semantic proximity Read ↗

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.Semantic proximity Read ↗

EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression.Semantic proximity Read ↗

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.Semantic proximity Read ↗

CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinomaSemantic proximity Read ↗

Cooperation between SIX1 and DHX9 transcriptionally regulates integrin-focal adhesion signaling mediated metastasis and sunitinib resistance in KIRCSemantic proximity Read ↗

The ALOX5 inhibitor zileuton promotes sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.